Top Page
Shandong Weigao Group Medical Polymer Co
(1066)
Shandong Weigao Group Medical Polymer Co (1066) vs. iShares MSCI Hong Kong ETF (EWH)
Shandong Weigao Group Medical Polymer Co Business Overview & Revenue Model
Shandong Weigao Group Medical Polymer Co Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.10B | 13.09B | 13.23B | 13.62B | 13.15B | 11.62B |
| Gross Profit | 6.46B | 6.58B | 6.64B | 7.31B | 7.35B | 6.46B |
| EBITDA | 3.08B | 3.14B | 3.55B | 4.38B | 3.75B | 3.09B |
| Net Income | 1.97B | 2.07B | 2.00B | 2.76B | 2.28B | 2.09B |
Balance Sheet | ||||||
| Total Assets | 36.14B | 34.76B | 33.67B | 33.20B | 30.37B | 27.34B |
| Cash, Cash Equivalents and Short-Term Investments | 9.65B | 8.32B | 7.33B | 7.49B | 7.13B | 6.14B |
| Total Debt | 5.51B | 4.19B | 4.17B | 4.49B | 4.14B | 4.32B |
| Total Liabilities | 10.45B | 9.42B | 9.68B | 9.75B | 9.46B | 8.95B |
| Stockholders Equity | 24.10B | 23.75B | 22.45B | 21.67B | 19.27B | 17.55B |
Cash Flow | ||||||
| Free Cash Flow | 2.05B | 2.19B | 2.11B | 1.10B | 1.92B | 1.70B |
| Operating Cash Flow | 2.65B | 2.79B | 2.80B | 2.21B | 3.04B | 2.70B |
| Investing Cash Flow | -2.21B | -1.10B | -1.39B | -2.57B | -1.48B | 423.22M |
| Financing Cash Flow | -500.93M | -1.60B | -2.16B | -1.02B | -547.92M | -1.79B |
Shandong Weigao Group Medical Polymer Co Technical Analysis
Shandong Weigao Group Medical Polymer Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$1.60B | 6.78 | 3.68% | 7.46% | 21.39% | -0.57% | |
74 Outperform | HK$5.34B | 3.51 | 16.76% | 3.65% | 6.87% | 18.37% | |
72 Outperform | HK$28.19B | 14.57 | 24.01% | 0.63% | 13.58% | 24.59% | |
70 Neutral | HK$6.43B | 10.07 | 10.31% | ― | 14.06% | 3.02% | |
68 Neutral | HK$21.35B | 6.33 | 8.34% | 4.58% | 0.74% | 2.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Shandong Weigao Group Medical Polymer Co Corporate Events
Shandong Weigao Group Medical Polymer Company Limited has convened its first extraordinary general meeting of 2026 for 12 February in Weihai, Shandong, seeking shareholder approval for a series of transaction documents, including a sale and purchase agreement, a compensation agreement and a letter of non-competition undertakings. The board is asking shareholders to ratify these agreements and to authorise any director to execute all necessary actions and documentation, a move that, once approved, will formalise the contemplated transactions and potentially reshape parts of the group’s structure and competitive arrangements within the wider Weigao ecosystem.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited has entered into a supplemental sale and purchase agreement with related parties to finalise the terms of transferring 100% equity interest in its non-wholly-owned subsidiary WEGO Prefills to Weigao Blood Purification for a consideration of approximately RMB8.51 billion, to be settled via the issuance of 271,997,882 new shares in Weigao Blood Purification. Upon completion, WEGO Prefills will become a wholly owned subsidiary of Weigao Blood Purification, while Weigao Group’s aggregate stake in Weigao Blood Purification will rise from 23.53% to 52.10%, turning Weigao Blood Purification into a subsidiary of the listed company and bringing both WEGO Prefills and Weigao Blood Purification (and their subsidiaries) under full consolidation into Weigao’s financial statements; given the transaction size and the connected nature of the parties under common control of ultimate shareholder Mr. Chen Xueli, the deal is classified as a major and connected transaction and will be subject to Hong Kong Listing Rules requirements for reporting, announcement and independent shareholders’ approval.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited announced that its extraordinary general meeting held on 19 December 2025 approved all resolutions by poll, including framework agreements for purchases and logistic support services, the reappointment of independent non-executive director Li Qiang, and a change in company type. The strong shareholder support—despite required abstentions by controlling shareholder Weigao Holding and its associates on the related-party framework agreements—clears the way for the group to proceed with its intra-group procurement and logistics arrangements, reinforces its board structure, and enables a corporate restructuring step that may have implications for its future regulatory positioning and operational flexibility.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited has announced the postponement of its Extraordinary General Meeting (EGM) originally scheduled for 17 December 2025, now rescheduled to 19 December 2025 due to work arrangement coordination. The change also affects the book closure period and record date for shareholders, with the register of members for H Shares closed from 16 December to 19 December 2025, and the record date set for 19 December 2025. These adjustments ensure shareholders have the opportunity to attend and vote at the rescheduled EGM.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited has announced an extraordinary general meeting to be held on December 17, 2025, to discuss and approve several key resolutions. These include the approval of the Purchase Framework Agreement and the Logistic Support Services Framework Agreement, the reappointment of Mr. Li Qiang as an independent non-executive director, and a change in the company type. These resolutions are expected to impact the company’s operational strategies and governance structure.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited has announced the renewal of its existing continuing connected transactions through Supplemental Agreements with Weigao Holding and its subsidiaries. These agreements involve revising the annual cap for 2025 and extending the terms of the CCT Agreements to 2027. The transactions, which are subject to certain reporting and approval requirements under the Listing Rules, reflect the company’s strategic efforts to maintain and strengthen its business relationships and operational framework.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited has announced the formation of a joint venture with PT Oneject Indonesia, named Oneject Wego Medical, to manufacture and sell medical consumables in Indonesia. This strategic move aims to tap into the Indonesian market by leveraging local production capabilities and reducing reliance on imports, thereby expanding Weigao’s overseas market presence and customer base.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.
Shandong Weigao Group Medical Polymer Company Limited reported a 2.6% year-on-year revenue increase for the third quarter, reaching approximately RMB3.26 billion. The orthopedic, interventional, and blood management segments saw significant growth, while pharma packaging and medical devices faced challenges due to pricing pressures from government policies, impacting overall sales revenue growth.
The most recent analyst rating on (HK:1066) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Shandong Weigao Group Medical Polymer Co stock, see the HK:1066 Stock Forecast page.